DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2019 年 10 月 28 日 1:30 下午 - 2019 年 10 月 28 日 5:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Short Course: How Much is Enough? Best Practices and Principles for the Non-Lead Constituent Part Within a Regulatory Submission for a Combination Product

概览

Short Course* Registration: 12:30-5:00PM

This short course will provide an overview on the best practices for assembling a marketing application for a combination product. FDA’s current thinking is that a single application is generally appropriate for a combination product, the type of application depending on the primary mode of action (PMOA) of the product. In determining the information needed to demonstrate the safety and effectiveness of the product as a whole, the statutes and regulations pertaining to each constituent part must be considered.

The course will highlight two application types: a drug/device (drug-led) application, and a device/drug (device-led) application. For each type, content options to include for the non-lead constituent part will be discussed. The impact of complexity of the non-lead constituent part on the best content option will be examined. Case studies with open discussions and dialogue will be used throughout the course.

*Short Courses are not included in the meeting registration and require a separate fee.

学习目标

At the conclusion of this session, participants should be able to:
  • Identify the types of marketing applications for combination products
  • Outline best practices in developing a marketing application including the non-lead constituent part
  • Describe the challenges and opportunities on determining the how much non-lead constituent part data is required and where the data should be referenced within the marketing application

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。